


Amendments to the Claims



1. (Currently Amended) A compound of Formula I



wherein:

Q is CH or N;

R¹ is tetrazolyl, MeCONHSO₂⁻, PhCONHSO₂⁻, R⁵O₂C(CH₂)₀₋₃CONHSO₂⁻,






R² is R⁶, -CH₂Ar¹, -CHPh₂, -CH₂CO(4-FPh), -CH₂CO(4-CF₃Ph), or -CH₂CONp where Np is naphthyl;

R³ is C₅₋₇cycloalkyl;

R⁴ is hydrogen, Ar², or Ar³;

Ar¹ is selected from the following group: phenyl, halophenyl,






Ar² is phenyl, naphthyl, or biphenyl, optionally substituted with 1-3 substituents selected from the group comprising halogen, C₁₋₆ alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆sulfoxy, C₁₋₂perfluoroalkyl, hydroxy, formyl, C₁₋₆alkylcarbonyl, cyano, nitro, C₁₋₆alkylamido, CO₂R⁵, CONR⁵R⁵, C₁₋₆alkylsulfonamido, and dioxolane;

Ar³ is thienyl, furanyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl, quinoliny, or pyrimidinyl optionally substituted with 1-2 substituents selected from the group comprising C₁₋₆alkyl, formyl, acetoxy, trifluoroacetoxy, and t-butoxycarbonyl;

R⁵ is hydrogen or C₁₋₆alkyl;

R⁶ is halogen, methoxy, CO₂R⁵ or CONR⁷R⁸;


R⁷ and R⁸ are independently hydrogen, C₁₋₆alkyl, -CH(Me)CO₂R⁵, -(CH₂)₁₋₃CO₂R⁵, -




(CH₂)₁₋₃CONR⁵R⁵, -(CH₂)₁₋₃OH, or R⁷ and R⁸ taken together with the nitrogen to which they are attached form pyrrolidine, morpholine, piperidine, 4-hydroxypiperidine, piperazine, or 4-methylpiperazine;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. (Original) A compound of claim 1 wherein R³ is cyclohexyl.



3. (Original) A compound of claim 1 wherein R¹ is tetrazolyl and R² is
4. (Original) A compound of claim 3 wherein R⁴ is Ar².
5. (Original) A compound of claim 4 wherein R³ is cyclohexyl.
6. (Original) A compound of claim 3 wherein R⁴ is Ar³.
7. (Original) A compound of claim 6 wherein R³ is cyclohexyl.
8. (Original) A compound of claim 3 wherein R⁴ is hydrogen.
9. (Original) A compound of claim 8 wherein R³ is cyclohexyl.
10. (Original) A compound of claim 1 wherein R² is -CH₂Ar¹.
11. (Original) A compound of claim 10 wherein R³ is cyclohexyl.
12. (Original) A composition useful for treating hepatitis C comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
13. (Original) A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.
14. (New) A compound of Formula Ia



Ia

wherein:

R¹ is tetrazolyl or MeCONHSO₂-;

R³ is C₅₋₇cycloalkyl;


R⁴ is phenyl substituted with halogen or cyano;

R⁶ is methoxy or CONR⁷R⁸;


R⁷ and R⁸ are independently hydrogen or C₁₋₆alkyl;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

15. (New) A compound of claim 14 selected from the group consisting of;



;



; and

